Activating the body’s innate healing ability to treat degenerative disease

Learn about our lead candidate, FX-322, a potential regenerative treatment for sensorineural hearing loss

Learn More

Working to Transform the Treatment of Hearing Loss

Frequency’s lead product candidate, FX-322, is designed to activate progenitor cells in the ear to regenerate damaged auditory cells and improve hearing function. FX-322 targets a condition known as sensorineural hearing loss, or SNHL, which impacts more than 90 percent of all people with hearing loss.

FX-322 aims to repair the underlying cause of SNHL and improve overall sound clarity and intelligibility, moving beyond today’s standard of care which focuses on sound amplification.

Learn More

Our Progenitor Cell Activation Approach

Frequency is a leader in the discovery and development of therapeutics that activate progenitor cells for the treatment of degenerative diseases.

Our small molecule approach aims to activate progenitor cells in specific damaged or injured tissues throughout the body in order to create healthy functional tissues and organs.

Learn More


July 17, 2020

Frequency Therapeutics Announces $42 Million Private Placement

Read More

May 27, 2020

Frequency Therapeutics to Present at Upcoming Investor Conferences

Read More

May 14, 2020

Frequency Therapeutics Provides Business Updates and Reports First Quarter 2020 Financial Results

Read More

Join Our Team

Learn more about Frequency, our team and culture, and opportunities to grow your career.

Learn More